You are here: Industry Insights > NASH

News List

Integral Molecular Awarded $1.4 Million by NIH americanpharmaceuticalreview
December 05, 2018
Integral Molecular was awarded $1.4M by the NIH to develop its lead antibodies against cannabinoid receptor 1 (CB1) for treating the liver disease nonalcoholic.....
Genentech buys NASH biotech Jecure pharmaphorum
November 30, 2018
Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH.
Roche's Genentech to acquire inflammatory drug discovery firm Jecure pharmafile
November 29, 2018
Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of drugs to treat serious inflammatory conditions...
Roche inks deal to purchase Jecure Therapeutics firstwordpharma
November 28, 2018
Roche's Genentech unit has entered into a definitive agreement to acquire Jecure Therapeutics, obtaining full rights to the latter’s entire preclinical portfolio of NLRP3 inhibitors, Jecure announced Tuesday. Financial terms of the deal were not divulged.
Roche inks deal to purchase Jecure Therapeutics firstwordpharma
November 28, 2018
Roche's Genentech unit has entered into a definitive agreement to acquire Jecure Therapeutics, obtaining full rights to the latter’s entire preclinical portfolio of NLRP3 inhibitors, Jecure announced Tuesday. Financial terms of the deal were not divulged.
Novartis and Pfizer link to develop NASH combo therapy pharmatimes
November 01, 2018
Novartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease...
Pfizer and Novartis partner up to develop combo therapies for NASH pharmafile
October 31, 2018
Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or more combo therapies for the treatment of non-alcoholic steatohepatitis (NASH).
Novartis, Pfizer Partner for NASH contractpharma
October 30, 2018
Novartis, Pfizer Partner for NASH
Novartis Announces Clinical Collaboration with Pfizer americanpharmaceuticalreview
October 30, 2018
Novartis Announces Clinical Collaboration with Pfizer
AZ buys Ionis’ NASH candidate pharmatimes
April 11, 2018
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page